Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence from the KEYNOTE-564 trial indicates that pembrolizumab improves disease-free survival (DFS) compared to placebo, with a hazard ratio of 0.63. However, the data is described as immature, which introduces some uncertainty regarding the long-term effectiveness. While there is a moderate benefit shown, the lack of mature data prevents a higher rating.
Cost effectiveness
The cost-effectiveness estimates for pembrolizumab are within the range that NICE considers acceptable for Healthcare resources. The committee concluded that the ICERs, even with some uncertainty, support its use as a cost-effective option for adjuvant treatment.
Quality of life
The document discusses the side effects of current treatments for renal cell carcinoma, which can severely affect quality of life. However, it does not provide specific data on HRQoL improvements associated with pembrolizumab. The absence of validated tools or significant evidence of quality-of-life gains leads to a rating of minimal impact.
Supporting Domains
Safety and Adverse Effects
While there are more grade 3 to 5 adverse events reported with pembrolizumab compared to placebo, the committee acknowledged that this is expected with active immunotherapy. The overall safety profile is acceptable, with manageable adverse events, justifying a good rating.
Comparator Selection
Pembrolizumab was compared against placebo in a well-designed phase 3 trial, which is appropriate for assessing its effectiveness. The committee found the comparator selection to be strong, with no significant gaps.
Patient Population and Subgroups
The trial population is aligned with the marketing authorization, focusing on adults with renal cell carcinoma at increased risk of recurrence after nephrectomy. The committee found the population to be generalizable to the Healthcare, supporting a good rating.
Care Pathway Integration
Pembrolizumab can be integrated into existing treatment pathways with minor adjustments, such as routine surveillance. The committee noted that the treatment regimen is manageable within current clinical practice, justifying a strong rating.
Resource Use and Cost Implications
The document indicates that pembrolizumab is likely to be cost-effective and manageable within Healthcare budgets, with a commercial arrangement providing a discount. This suggests a favorable impact on resource use.
Evidence Quality and Robustness
The evidence is based on a phase 3 RCT, which is a strong design. However, the immaturity of the data introduces some concerns about robustness. Overall, the evidence quality is acceptable but not without limitations.
Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty regarding the long-term effectiveness of pembrolizumab, particularly concerning the duration of treatment effects and the risk of relapse. This uncertainty may affect its broader impacts and decision-making.
